The DOI matches its Crossref record.
Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients
Abstract
New-onset diabetes (NOD) is associated with transplant failure. A few single-center studies have suggested that sirolimus is associated with NOD, but this is not well established. With the use of data from the United States Renal Data System, this study evaluated the association between sirolimus use at the time of transplantation and NOD among 20,124 adult recipients of a first kidney transplant without diabetes. Compared with patients treated with cyclosporine and either mycophenolate mofetil orazathioprine, sirolimus-treated patients were at increased risk for NOD, whether it was used in combination with cyclosporine (adjusted hazard ratio [HR] 1.61; 95% confidence interval [CI] 1.36 to 1.90),tacrolimus (adjusted HR 1.66; 95% CI 1.42 to 1.93), or an antimetabolite (mycophenolate mofetil orazathioprine; adjusted HR 1.36; 95% CI 1.09 to 1.69). Similar results were obtained in a subgroup analysis that included the 16,861 patients who did not have their immunosuppressive regimen changed throughout the first posttransplantation year. In conclusion, sirolimus is independently associated with NOD. Given the negative impact of NOD on posttransplantation outcomes, these findings should be confirmed in prospective studies or in meta-analyses of existing trials that involved sirolimus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Chronic treatment of humans with high doses of rapalogs is also associated with deleterious metabolic consequences including hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, insulin resistance and glucose intolerance 139–143.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [141]
Citations
Cited by
Sorted by citations
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Sharif, A., Hecking, M., de Vries, A. P. J., Porrini, E., Hornum, M., Rasoul-Rockenschaub, S., Berlakovich, G., Krebs, M., Kautzky-Willer, A., Schernthaner, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12850 · Cited by 532
“Johnston et al, analyzing data from the United States Renal Data System, found sirolimus were independently associated with increased risk for PTDM (38).”
Targeting the biology of aging with mTOR inhibitors
Mannick, J. B., & Lamming, D. W. (2023) · Nature Aging · doi:10.1038/s43587-023-00416-y · Cited by 372
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Shivaswamy, V., Boerner, B., & Larsen, J. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1084 · Cited by 328
mTOR signaling in cellular and organismal energetics
Albert, V., & Hall, M. N. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2014.12.001 · Cited by 304
Adverse events associated with mTOR inhibitors
Pallet, N., & Legendre, C. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752814 · Cited by 198
Proteostasis in cardiac health and disease
Henning, R. H., & Brundel, B. J. J. M. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.89 · Cited by 193
Vanrenterghem, Y., Bresnahan, B., Campistol, J., Durrbach, A., Grinyó, J., Neumayer, H.-H., Lang, P., Larsen, C. P., Mancilla-Urrea, E., Pestana, J. M., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e31820c10eb · Cited by 183
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
The Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging
Zhang, Y., Zhang, J., & Wang, S. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101376 · Cited by 92
Metabolic consequences of modern immunosuppressive agents in solid organ transplantation
Bamgbola, O. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816641580 · Cited by 85
Claes, K., Meier-Kriesche, H.-U., Schold, J. D., Vanrenterghem, Y., Halloran, P. F., & Ekberg, H. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr238 · Cited by 75
Fasting and rapamycin: diabetes versus benevolent glucose intolerance
Blagosklonny, M. V. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1822-8 · Cited by 74
Rapamycin-induced metabolic defects are reversible in both lean and obese mice
Liu, Y., Diaz, V., Fernandez, E., Strong, R., Ye, L., Baur, J. A., Lamming, D. W., Richardson, A., & Salmon, A. B. (2014) · Aging · doi:10.18632/aging.100688 · Cited by 68
Impaired glucose homeostasis in renal transplant recipients receiving basiliximab
Aasebo, W., Midtvedt, K., Valderhaug, T. G., Leivestad, T., Hartmann, A., Reisaeter, A. V., Jenssen, T., & Holdaas, H. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp617 · Cited by 38
Hyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Cheng, C.-Y., Chen, C.-H., Wu, M.-F., Wu, M.-J., Chen, J.-P., Liu, Y.-M., Hou, Y.-C., & Wang, H.-Y. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17124581 · Cited by 18
Kim, H. D., Chang, J.-Y., Chung, B. H., Kim, C.-D., Lee, S.-H., Kim, Y. H., & Yang, C. W. (2021) · Annals of Transplantation · doi:10.12659/aot.927984 · Cited by 17
Post-transplantation diabetes mellitus in pediatric patients
Grundman, J. B., Wolfsdorf, J. I., & Marks, B. E. (2020) · Hormone Research in Paediatrics · doi:10.1159/000514988 · Cited by 12
Metadata
- Authors
- Johnston, O., Rose, C. L., Webster, A. C., & Gill, J. S.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2008-07
- Volume
- 19
- Issue
- 7
- Pages
- 1411-1418
- ISSN
- 1046-6673
- Cited by
- 359
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
